And, of course, that carries with it up to $6 million in clinical milestones for each indication (x4) and up to another $29 million in commercial milestones. Every bit of non-dilutive cash helps!
Oh, lifter... you know if he/she answered that, it'd defeat the purpose of being called "one and only post".
Yeah, here it is... from the December 9, 2013 PR:
"GBP will be responsible for all clinical development and commercialization costs in the GBP territory. In collaboration with Advaxis, GBP will also identify and pay the clinical trial costs for up to 150 patients with cervical cancer for enrollment in Advaxis’ U.S. and GBP’s Asia registrational programs for cervical cancer."
And I could swear that Global Biopharma is also chipping in money to fund up to 150 patients as well.
Sorry, bud. You were over by a mere 25,420 shares... no free soup for you. :-)
LOL. I guess since my bet is so much more conservative than others thus far, I can round down to 7.3 million....
I'm going to place my bet on how many short marbles are in the jar -- 7.334 million.
Or they could just lay off. Those with the problem already have the solution -- to hit the ignore button. While it's true whatever happens happens, It's clear you are a long term investor who is optimistic about ADXS, and I for one find it refreshing.